In part 2 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses what industry should be keeping top of mind when it comes to designing and executing pain clinical studies.
ACT: What should industry be keeping top of mind when it comes to designing and executing pain clinical trials?
Greg Sturmer: I guess the first part is kind of, regardless of whether it's pain, or another indication is what's always of utmost importance is to keep the end in mind. And the end in this case is, what do I want in my product label? What's going to be in that label? Because the information that's in the label is what the company is going to be able to use to market that product. So, what the focus should be on is: how are we going to differentiate our product from what else is out there? So, I mean, the Nirvana is: I'm going to improve on safety, and have a very specific set of clinical studies that support that I've got a product that's much safer than what's out on the market. And/or I suppose, efficacy, I can set myself apart from the competition, because I've got a more effective medication. So I think designing your studies from a safety perspective that says, “Here is the data that shows that we're better than the current product that leads in the market space as it applies to us.” That's why our focus is on what we call SMART products. That acronym stands for safer medicines that alleviate risks and trauma. And our effort is to create smart medicines, in pain, smart medicines for opioid use disorder, and smart rescue agents. When it comes to efficacy when you're trying to differentiate a product from the market, let's bring it to the pain space. There's been a concerted effort over the decades to develop a non-opioid pain reliever that's as or more effective than opioids. And that's a high bar, because opioids have unmatched efficacy and are unmatched across a spectrum of causes of pain. So, I would say the important thing to do when designing your clinical study is to go head-to-head with whatever is the standard of care. And in the case of pain, opioids, and demonstrate how are you better.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.